[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360682-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-360682-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","glucagon-like-peptide-1-receptor-agonist-use-and-risk-of-gynecologic-cancers-a-meta-analysis-of-multinational-real-world-cohort-studies","Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers - a meta-analysis of multinational real-world cohort studies","","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for type 2 diabetes mellitus and obesity, yet their relationship with gynecologic malignancies remains insufficiently clarified. A meta-analysis of real-world observational cohort studies pooled hazard ratios from random-effects models to assess overall and subtype cancer outcomes. Results showed no significant link with overall gynecologic cancer risk, while ovarian cancer risk appeared reduced; evidence heterogeneity supports cautious interpretation.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/glucagon-like-peptide-1-receptor-agonist-use-and-risk-of-gynecologic-cancers-a-meta-analysis-of-multinational-real-world-cohort-studies/360682/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/glucagon-like-peptide-1-receptor-agonist-use-and-risk-of-gynecologic-cancers-a-meta-analysis-of-multinational-real-world-cohort-studies/360682.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study objective regarding GLP-1 receptor agonists?","Question",{"text":63,"@type":64},"To evaluate whether GLP-1 receptor agonist use is associated with the risk of gynecologic cancer outcomes based on real-world cohort evidence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the studies selected and analyzed?",{"text":68,"@type":64},"Observational cohort studies were systematically searched in PubMed and Embase up to February 15, 2026, and hazard ratios with 95% confidence intervals were pooled using random-effects models.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the meta-analysis find for overall gynecologic cancer risk?",{"text":72,"@type":64},"GLP-1RA use was not significantly associated with overall gynecologic cancer risk (HR 0.80; 95% CI 0.63, 1.01).",{"name":74,"@type":61,"acceptedAnswer":75},"Were any cancer subtypes associated with GLP-1RA use?",{"text":76,"@type":64},"In subtype analyses, a reduced risk was observed for ovarian cancer (HR 0.68; 95% CI 0.49, 0.93), while associations for endometrial, cervical, and other gynecologic cancers were not statistically significant.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},360682,1791162541,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Preventive Medicine Reports 68 (2026) 103548  \nContents lists available at ScienceDirect  \nPreventive Medicine Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/pmedr)[ www.elsevier.com/locate/pmedr](homepage: www.elsevier.com/locate/pmedr)  \n| Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies\u003Cbr>Rongxia Lia,b,1, Xuewei Zhao c,1, Jinhai Shend,e,f, Bo Luod, Yongmei Wang g,*, Yancang Duan h,i,j,**\u003Cbr>a School of Basic Medical Science, Hebei University of Chinese Medicine, Shijiazhuang, Hebei Province 050091, PR China b Department of Gynecology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050004, PR China c Department of Gynecology, the Fourth Hospital of Shijiazhuang City, Shijiazhuang, Hebei Province 050011, PR China d State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China\u003Cbr>e Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China f School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China g Department of Gynecology, the First Hospital of Tsinghua University, Beijing 100016, PR China\u003Cbr>h College of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei Province 050091, China i Hebei Collaborative Innovation Center of Integrated Chinese and Western Medicine on Reproductive Disease, Shijiazhuang, Hebei Province 050091, China j Hebei Key Laboratory of Integrative Medicine on Liver-kidney Patterns, Shijiazhuang, Hebei Province 050091, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>Glucagon-like peptide-1 receptor agonists Gynecologic cancers\u003Cbr>Endometrial cancer Ovarian cancer Meta-analysis |  | Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes mellitus (T2DM) and obesity. Given the established links between metabolic dysfunction and gynecologic malignancies, the potential association between GLP-1RA use and gynecologic cancer risk remains clinically relevant but incompletely defined. We conducted a meta-analysis of real-world cohort studies to evaluate this association.\u003Cbr>Methods: We systematically searched PubMed (from 1966) and Embase (from 1974) through February 15, 2026 for observational cohort studies assessing the association between (GLP-1 RA) use and gynecologic cancer outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Results: Nine retrospective cohort studies were included. GLP-1RA use was not significantly associated with gynecologic cancer risk (HR 0.80; 95% CI: 0.63, 1.01). In cancer subtype analyses, a reduced risk was observed for ovarian cancer (HR 0.68; 95% CI: 0.49, 0.93), whereas associations for endometrial, cervical, and other gynecologic cancers were not statistically significant.\u003Cbr>Conclusions: GLP-1RA use was not significantly associated with overall gynecologic cancer risk, although potential reductions were observed in obesity populations and for ovarian cancer. Given substantial heterogeneity and the observational nature of the evidence, these findings should be interpreted cautiously and considered hypothesis-generating. |\n\n1. Introduction  \nObesity and type 2 diabetes mellitus (T2DM) are well-established risk factors for multiple malignancies, particularly gynecologic cancers such as endometrial and ovarian cancer (Pati et al., 2023; Espinoza et al., 2026). Among these, endometrial cancer exhibits one of the strongest  \nassociations with excess adiposity, hyperinsulinemia, and unopposed estrogen exposure (Kiesel et al., 2020; Huang et al., 2023). Obesityrelated chronic inflammation, insulin resistance, and hormonal dysregulation are also implicated in ovarian carcinog","cbCaiuEhemW5RHNH","https://ap.wps.com/l/cbCaiuEhemW5RHNH","pdf",4503705,"English","# Objective\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the study objective regarding GLP-1 receptor agonists?\",\"answer\":\"To evaluate whether GLP-1 receptor agonist use is associated with the risk of gynecologic cancer outcomes based on real-world cohort evidence.\"},{\"question\":\"How were the studies selected and analyzed?\",\"answer\":\"Observational cohort studies were systematically searched in PubMed and Embase up to February 15, 2026, and hazard ratios with 95% confidence intervals were pooled using random-effects models.\"},{\"question\":\"What did the meta-analysis find for overall gynecologic cancer risk?\",\"answer\":\"GLP-1RA use was not significantly associated with overall gynecologic cancer risk (HR 0.80; 95% CI 0.63, 1.01).\"},{\"question\":\"Were any cancer subtypes associated with GLP-1RA use?\",\"answer\":\"In subtype analyses, a reduced risk was observed for ovarian cancer (HR 0.68; 95% CI 0.49, 0.93), while associations for endometrial, cervical, and other gynecologic cancers were not statistically significant.\"}]","Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers - a meta-analysis of multinational real-world cohort studies | PDF",1790141122,23,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83f6eecca75d7b2cfb0c136e0300e2c0.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4cfdfd1e5342e2fdb65179dc390f178.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d4c7a2a988809354a9b2fb276aca24f.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c67f244e73776f45622313e129502e53.webp",980,1306]